Graham Center One-Pager

Mind the Gap: Medicare Part D’s Coverage Gaps May Affect Patient Adherence



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2006 Feb 1;73(3):404.

Medicare Part D will lower medication expenditures for many older patients. However, its complex design incorporates a staggered series of cost-sharing mechanisms that create gaps in coverage and may have a negative impact on medication adherence.

Part D’s staggered cost-sharing mechanisms (i.e., a deductible, a coinsurance zone, a “doughnut hole,” and a catastrophic limit)1 will produce coverage gaps for individual patients—periods within any year where they are responsible for 100 percent of their medication costs. Although many prescription drug plans will eliminate deductibles and replace the 25 percent coinsurance zone with tiered co-pays, the majority will preserve the doughnut hole. This is the most significant cost-sharing mechanism and creates the biggest potential coverage gaps for patients.

To illustrate potential coverage gaps experienced under Part D, take the example of Mrs. Jones. She makes $19,000 per year (twice the federal poverty level) and spends $250 per month on medications ($3,000 annually). Under Part D she pays the first $250 of drug costs as a deductible, thus experiencing a coverage gap in her first month of enrollment. Over the next eight months, she spends another $2,000, of which she is responsible for 25 percent, or $500. Medicare covers the remaining $1,500. Her drug expenses now total $2,250, putting her into the doughnut hole. For the remaining three months of the year, she pays 100 percent of drug costs, or $750. By the end of the year, she has spent around $1,500 out of pocket on prescription drugs and another $384 ($32 per month) in premiums to take part in the plan. Medicare has spent $1,500. Overall, the patient has had four months of coverage gaps when she paid 100 percent of drug costs.

The 7 million beneficiaries projected to spend into the doughnut hole and beyond will have gaps in coverage that last from 1.5 to 7.2 months.1,2 This gap grows or shrinks based on total annual drug costs (see accompanying figure).2 A study3 of Medicare beneficiaries with drug spending limits and subsequent gaps in coverage similar to those resulting from Part D’s doughnut hole suggests that such patients are significantly more likely to engage in cost-lowering strategies such as taking less medication than prescribed or switching to cheaper medications. Two thirds of patients had difficulty paying for prescriptions, and this overall greater financial burden potentially jeopardizes other necessities such as housing and utilities.3

Coverage Gap Based on Drug Costs

Figure.

Number of months with coverage gaps under Medicare Part D based on total annual drug costs.

Information from reference 2.

View Large

Coverage Gap Based on Drug Costs


Figure.

Number of months with coverage gaps under Medicare Part D based on total annual drug costs.

Information from reference 2.

Coverage Gap Based on Drug Costs


Figure.

Number of months with coverage gaps under Medicare Part D based on total annual drug costs.

Information from reference 2.

Part D will reduce the burden of prescription costs for most beneficiaries, but physicians should expect differing effects on individual patients depending on their coverage gaps. Efforts by benefit plan organizers and policy makers to smooth the month-to-month variability in coverage will be essential to maximize the positive impacts of Part D.

REFERENCES

1. Estimates of Medicare beneficiaries’ out-of-pocket drug spending in 2006. Menlo Park, Calif.: Actuarial Research Corporation and The Henry J. Kaiser Family Foundation, 2004.

2. Stuart B, Briesacher BA, Shea DG, Cooper B, Baysac FS, Limcangco MR. Riding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit. Health Aff. 2005;24:1022–31.

3. Tseng C, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292:952–60.

note: The information and opinions contained in research from the Graham Center do not necessarily reflect the views or the policy of the AAFP.

Adapted from the Graham Center One-Pager #43. Mallya G, Bazemore AW, Phillips RL, Green LA, Klein LS, Dodoo MS. Mind the gap: Medicare Part D’s coverage gaps may affect patient adherence. February 2006. Available online at http://www.graham-center.org/onepager43.xml. From the Robert Graham Center: Policy Studies in Family Medicine and Primary Care, 1350 Connecticut Ave., NW, Suite 201, Washington, DC 20036 (telephone: 202–331–3360; fax: 202–331–3374; e-mail: policy@aafp.org).

 

Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article